COMPASS Pathways (NASDAQ:CMPS) Issues Quarterly Earnings Results

COMPASS Pathways (NASDAQ:CMPS) released its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04, Zacks reports. During the same quarter last year, the company earned ($0.67) EPS.

COMPASS Pathways Trading Down 0.2 %

NASDAQ:CMPS traded down $0.01 on Friday, reaching $4.75. The company’s stock had a trading volume of 2,081,860 shares, compared to its average volume of 874,967. COMPASS Pathways has a 1-year low of $4.05 and a 1-year high of $12.75. The business’s 50-day moving average price is $6.61 and its two-hundred day moving average price is $7.04. The firm has a market cap of $324.85 million, a PE ratio of -2.16 and a beta of 2.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03.

Analyst Ratings Changes

CMPS has been the topic of several analyst reports. Maxim Group cut their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday. Canaccord Genuity Group cut their price target on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. HC Wainwright cut their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Royal Bank of Canada decreased their target price on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $30.67.

Insider Transactions at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares of the company’s stock, valued at approximately $41,779,932.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.25% of the stock is currently owned by insiders.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.